Letter Agreement Clarifying Technology Definition under License Agreement between CIMA Laboratories Inc. and IPR Pharmaceuticals Inc.

Summary

This letter agreement, dated August 29, 2002, is between AstraZeneca (on behalf of IPR Pharmaceuticals Inc.) and CIMA Laboratories Inc. It clarifies that the term 'OraSolv Technology' in their original 1999 license agreement also includes 'DuraSolv Technology' and any related improvements, as used in the manufacture of Zomig Rapimelt tablets. CIMA Laboratories confirms this understanding by signing the letter, ensuring both parties agree on the technology covered by the agreement.

EX-10.5 7 c78994exv10w5.txt EX-10.5 LETTER AGREEMENT, DATED AUGUST 29, 2002 EXHIBIT 10.5 [ASTRAZENECA LETTERHEAD] John Siebert CIMA Laboratories Inc 29 August 2002 Our Ref: Your Ref: Tel: Fax: Agt/Comm/Cima/Lic & Supply +44 1625 230089 +44 1625 514061 Dear John LICENSE AGREEMENT DATED 28 MAY 1999 BETWEEN CIMA LABORATORIES INC AND IPR PHARMACEUTICALS INC (THE "AGREEMENT") We note that the Agreement historically refers to OraSolv Technology in relation to the production of fastmelt tablets and are aware that under the resulting Supply Agreement, DuraSolv Technology is being utilized to produce fastmelt tablets. We therefore would appreciate it if you could sign and return a copy of this letter to us to confirm that the definition of OraSolv Technology in the Agreement includes the DuraSolv Technology used at present (plus any associated improvements as defined in the Agreement) in the manufacture of Zomig Rapimelt tablets. Many thanks for your assistance in this clarification. Yours sincerely, Ken Tinebo Supply Chain & Logistics Signed and Accepted on behalf of CIMA Laboratories Inc by /s/ John M. Siebert 30 Aug, 2002 - ------------------------------------------------------- John Siebert